Vulvar melanoma is a rare but aggressive form of skin cancer that develops on the outer female genitalia, accounting for approximately 5–10% of all vulvar cancers. Because it is uncommon and its early symptoms can be subtle or mistaken for benign conditions, timely recognition and diagnosis are critical to improving outcomes.
Key Takeaways
- Vulvar melanoma is a rare malignancy that develops on the vulvar skin or mucous membranes, most commonly in postmenopausal women.
- Early stage disease is largely confined to the local tissue, offering the best opportunity for curative treatment.
- Common early warning signs include a changing pigmented lesion, itching, and unusual discoloration on the vulva.
- Diagnosis relies on dermoscopy, biopsy, and staging workup to guide treatment decisions.
- Five-year survival rates are significantly higher when the cancer is detected and treated in its early stages.
Vulvar Melanoma Stages and What They Mean
Staging is the process clinicians use to describe how far a cancer has spread, and it directly shapes treatment planning and prognosis. Vulvar melanoma is staged using the American Joint Committee on Cancer (AJCC) TNM system, which evaluates the tumor’s thickness (T), lymph node involvement (N), and the presence of distant metastasis (M). Unlike most vulvar cancers, which follow the FIGO gynecologic staging system, melanoma of the vulva is classified according to the same melanoma-specific criteria applied to cutaneous melanoma elsewhere on the body.
Breslow thickness — the depth of tumor invasion measured in millimeters from the skin surface — is the single most important factor in determining the T category. Tumors measuring 1 mm or less in thickness without ulceration are classified as Stage I, often subdivided into Stage IA (≤0.8 mm, no ulceration) and Stage IB (0.8–1 mm or any tumor ≤1 mm with ulceration). Stage II tumors exceed 1 mm in thickness but remain confined to the primary site without nodal spread. Stage III indicates regional lymph node involvement, while Stage IV reflects distant metastasis to organs such as the lungs, liver, or brain.
Understanding the vulvar melanoma stages and what they mean empowers patients to ask informed questions about their diagnosis. Early stages — particularly Stage I and Stage II — carry a far more favorable outlook than advanced disease. The presence of ulceration or satellite lesions can elevate a tumor to a higher stage even if lymph nodes remain uninvolved, underscoring why careful pathological assessment is essential from the moment a suspicious lesion is identified.
| Stage | Breslow Thickness | Ulceration / Nodes | Distant Metastasis |
|---|---|---|---|
| Stage IA | ≤ 0.8 mm | No ulceration; no nodes | None |
| Stage IB | 0.8–1 mm or ≤1 mm with ulceration | No nodes | None |
| Stage II | > 1 mm | No nodes | None |
| Stage III | Any | Regional node involvement | None |
| Stage IV | Any | Any | Present |
Signs and Symptoms of Early Stage Vulvar Melanoma
Recognizing the vulvar melanoma signs and symptoms in their earliest form is essential because the disease can closely mimic benign skin conditions such as lichen sclerosus, genital warts, or common moles. The lesion most often appears on the labia minora or clitoris, although it can arise anywhere on the vulvar surface, including the mucosal tissues. Many women first notice a pigmented spot or an existing mole that seems to be changing in color, shape, or size.
The ABCDE criteria — Asymmetry, Border irregularity, Color variation, Diameter greater than 6 mm, and Evolution — provide a useful framework for identifying suspicious lesions, even in a mucosal location. A vulvar lesion that displays multiple shades of brown, black, red, white, or blue, or one that develops an irregular or notched border, warrants prompt medical evaluation. Itching, burning, or a sensation of discomfort in the vulvar region are frequently reported early symptoms, though they are nonspecific and often dismissed as minor irritation.
Additional early stage vulvar melanoma presentations include:
- A new or changing dark spot or patch on the vulvar skin or mucosa
- Persistent itching or burning not explained by infection or dermatitis
- A lump or thickened area that may bleed with minimal contact
- Discoloration ranging from pink or red to deep brown or black
- A lesion that fails to heal after treatment for a presumed benign condition
Because the vulvar area is not routinely self-examined, many women delay seeking care. Clinicians recommend that any persistent vulvar change lasting more than two to four weeks be evaluated by a healthcare provider, particularly in women over 60, among whom incidence is highest. Early reporting of these changes can make a meaningful difference in treatment success.
How Early Stage Vulvar Melanoma Is Diagnosed and Treated
Accurate and timely diagnosis is the foundation of effective management. When a suspicious vulvar lesion is identified, the clinician typically begins with a thorough clinical examination supported by dermoscopy — a non-invasive technique that uses magnification and polarized light to examine pigmented structures beneath the skin surface. Dermoscopy improves diagnostic accuracy and helps differentiate melanoma from benign pigmented lesions without requiring immediate surgery.
A definitive diagnosis, however, always requires a tissue biopsy. An excisional biopsy — removing the entire lesion with a narrow margin — is the preferred method for small suspicious lesions because it provides the complete specimen needed to assess Breslow thickness, mitotic rate, and ulceration status. Punch or incisional biopsies may be used for larger lesions. The pathology report from the biopsy determines the T category and informs sentinel lymph node biopsy decisions for tumors thicker than 0.8 mm.
For early stage vulvar melanoma diagnosis and treatment, the primary intervention is wide local excision (WLE) with margins of at least 1 cm for tumors up to 1 mm thick, and 2 cm for thicker lesions. Sentinel lymph node biopsy (SLNB) is recommended for tumors thicker than 0.8 mm or those with ulceration to determine whether microscopic nodal spread has occurred. If the sentinel node is negative, complete lymph node dissection is generally avoided, reducing the risk of lymphedema and other surgical complications.
Adjuvant therapy is considered when pathological features suggest a higher risk of recurrence. Immune checkpoint inhibitors — such as anti-PD-1 agents — have transformed the adjuvant treatment landscape for high-risk resected melanoma, and their use is increasingly evaluated in vulvar melanoma based on data from cutaneous melanoma trials. Radiation therapy plays a limited role in early disease but may be considered in specific clinical scenarios where surgical margins are close or positive.
Prognosis and Survival Rate for Early Stage Vulvar Melanoma
Prognosis for vulvar melanoma is strongly influenced by stage at diagnosis, tumor thickness, the presence of ulceration, and lymph node status. Overall, vulvar melanoma carries a worse prognosis than cutaneous melanoma at other body sites, partly because diagnosis often occurs at a later stage and partly due to its mucosal biology. According to data published in gynecologic oncology literature, the five-year overall survival rate for all stages of vulvar melanoma combined ranges from approximately 27% to 50%, reflecting the high proportion of cases diagnosed at an advanced stage.
The early stage vulvar melanoma prognosis and survival rate picture is considerably more optimistic. Patients with Stage I disease — particularly those with thin tumors (≤1 mm) and no ulceration — can achieve five-year survival rates above 80–90% with appropriate surgical treatment. Stage II tumors, while still localized, carry a somewhat reduced survival probability due to greater depth of invasion, though outcomes remain meaningfully better than for nodal or metastatic disease.
Several prognostic factors influence individual outcomes beyond stage alone. These include the mitotic rate within the tumor, the presence of microsatellites or in-transit metastases, and the status of surgical margins following excision. Patients whose tumors harbor BRAF V600E or KIT mutations may benefit from targeted therapies if disease recurs, offering additional therapeutic avenues that were unavailable just a decade ago. Regular follow-up — typically every three to six months for the first two years — is essential to detect recurrence early, as most relapses occur within this window.
Multidisciplinary care involving gynecologic oncologists, dermatologists, medical oncologists, and reconstructive surgeons provides the most comprehensive approach to managing this disease. Participation in clinical trials is encouraged where available, as ongoing research continues to refine both surgical techniques and systemic therapy protocols for this rare malignancy.
Frequently Asked Questions
Is vulvar melanoma curable when caught at an early stage?
Early stage vulvar melanoma — particularly Stage IA and IB — is associated with high cure rates when treated with wide local excision and, where indicated, sentinel lymph node biopsy. Five-year survival for thin, node-negative tumors can exceed 80–90%. Complete surgical excision with clear margins is the most important factor in achieving long-term disease control. Regular follow-up after treatment is essential to detect any recurrence promptly.
Who is most at risk for developing vulvar melanoma?
Vulvar melanoma occurs most frequently in postmenopausal women, with peak incidence in the sixth and seventh decades of life. Risk factors include a personal or family history of melanoma, fair skin, a large number of atypical nevi, and immune suppression. Unlike cervical cancer, vulvar melanoma is not consistently linked to HPV infection. A prior history of cutaneous melanoma also increases the likelihood of a subsequent primary mucosal melanoma.
How often should women be monitored after early stage vulvar melanoma treatment?
After completing primary treatment, most guidelines recommend follow-up appointments every three to six months for the first two years, when the risk of recurrence is highest, and then annually thereafter. Each visit typically includes a thorough physical examination of the vulva and regional lymph nodes. Imaging studies may be ordered if new symptoms arise. Patients are also encouraged to perform regular self-examination and report any changes between scheduled visits without delay.
